PULMATRIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.794 USD | +0.81% |
|
-5.06% | -3.53% |
| May. 10 | Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 10 | Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M | MT |
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Companyâs proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Companyâs product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Companyâs therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.53% | 6.55M | |
| +5.33% | 111B | |
| +12.11% | 106B | |
| -12.56% | 22.24B | |
| -3.64% | 21.25B | |
| -6.03% | 18.97B | |
| -35.21% | 18.52B | |
| -10.86% | 16.81B | |
| +37.57% | 12.54B | |
| -26.24% | 8.09B |
- Stock Market
- Equities
- PULM Stock
- Funds and ETFs Pulmatrix, Inc.
